Group 2C: Brain Metastasis; Predictive Biomarkers



Wednesday, Dec 14
2:00 pm – 3:30 pm Eastern Time (US/New York)



Poster #OT3-08-01

A phase 1 trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer (aBC) and other solid tumors (PIKASSO-01, trial in progress)

Poster #P3-05-22:

Serum S100A8/S100A9 levels are associated with increased risk of brain metastasis in patients with aggressive breast cancer

Poster author Emilly Villodre, Ph.D. will attend this session

Mentor: Abigail Johnston, Esq

Abigail is a recovering lawyer, living in Florida with her husband and two boys, and has lived with de novo Stage IV Metastatic Breast Cancer (MBC) since 2017.  Advocacy and brining the patient voice to all levels of health care and research is her passion and Abigail is honored to serve as a mentor with GRASP as well as on the Inaugural Advisory Board.  You can find her musings on her blog, www.NoHalfMeasures.blog.

Twitter: @AMJohnston1315

Scientist: Vinton Cheng, M.D., Ph.D.

Vinton Cheng is an academic clinical lecturer at the University of Leeds and St James’s University Hospital, UK. He completed his DPhil at the University of Oxford, where he studied a molecularly targeted MRI contrast agent that was shown to improve detection of brain metastasis. Vinton enjoys working at the interface of different research disciplines and most recently spent a year working in the Focused Ultrasound group at the University of Virginia investigating how to enhance the immune response against brain metastasis. He is passionate about communicating science and collaborating with patients in the clinic to improve cancer care